Many faces of DAMPs in cancer therapy

Cell Death and Disease

Volumn 4, Issue 5, 2013, Pages

  Krysko, O ^a   Aaes, T Løve ^b,c   Bachert, C ^a   Vandenabeele, P ^b,c   Krysko, D V ^b,c  

^a GHENT UNIVERSITY HOSPITAL   (Belgium)

^b DEPARTMENT OF PLANT SYSTEMS BIOLOGY   (Belgium)

^c GHENT UNIVERSITY   (Belgium)

Author keywords

ATP; Calreticulin; HMGB1; Immunogenic cell death; TLRs

Indexed keywords

ADENOSINE TRIPHOSPHATE; ANTHRACYCLINE; CALRETICULIN; CELL PROTEIN; DOCETAXEL; EPIRUBICIN; HIGH MOBILITY GROUP B1 PROTEIN; INITIATION FACTOR 2ALPHA; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; NUCLEOTIDE BINDING OLIGOMERIZATION DOMAIN LIKE RECEPTOR; PATTERN RECOGNITION RECEPTOR; TEMOZOLOMIDE; TOLL LIKE RECEPTOR; TOLL LIKE RECEPTOR 4;

ANTINEOPLASTIC ACTIVITY; BREAST CANCER; CANCER GROWTH; CANCER THERAPY; CARCINOGENIC ACTIVITY; CARCINOGENICITY; CELL DAMAGE; CELL DEATH; CELL PROLIFERATION; CELL SURFACE; CYTOTOXIC T LYMPHOCYTE; DAMAGE ASSOCIATED MOLECULAR PATTERN; ENDOPLASMIC RETICULUM STRESS; HEAD AND NECK SQUAMOUS CELL CARCINOMA; HUMAN; IMMUNOGENIC CELL DEATH; IMMUNOGENICITY; LOSS OF FUNCTION MUTATION; METASTASIS; OXIDATION REDUCTION STATE; PRIORITY JOURNAL; REVIEW; SECRETORY PATHWAY; SIGNAL TRANSDUCTION; SINGLE NUCLEOTIDE POLYMORPHISM; TUMOR CELL; TUMOR MICROENVIRONMENT;

ADENOSINE TRIPHOSPHATE; ANTINEOPLASTIC AGENTS; APOPTOSIS; CALRETICULIN; CELL MEMBRANE; HMGB1 PROTEIN; HUMANS; NEOPLASMS; T-LYMPHOCYTES, CYTOTOXIC;

EID: 84879395771     PISSN: None     EISSN: 20414889     Source Type: Journal    
DOI: 10.1038/cddis.2013.156     Document Type: Review

References (78)

1. Matzinger P. Tolerance, danger, and the extended family. Annu Rev Immunol 1994; 12: 991-1045.
2. Krysko DV, Agostinis P, Krysko O, Garg AD, Bachert C, Lambrecht BN et al. Emerging role of damage-associated molecular patterns derived from mitochondria in inflammation. Trends Immunol 2011; 32: 157-164.
3. Garg AD, Nowis D, Golab J, Vandenabeele P, Krysko DV, Agostinis P. Immunogenic cell death, DAMPs and anticancer therapeutics: an emerging amalgamation. Biochim Biophys Acta 2010; 1805: 53-71.
4. Venereau E, Casalgrandi M, Schiraldi M, Antoine DJ, Cattaneo A, De Marchis F et al. Mutually exclusive redox forms of HMGB1 promote cell recruitment or proinflammatory cytokine release. J Exp Med 2012; 209: 1519-1528.
5. Yang H, Lundback P, Ottosson L, Erlandsson-Harris H, Venereau E, Bianchi ME et al. Redox modification of cysteine residues regulates the cytokine activity of high mobility group box-1 (HMGB1). Mol Med 2012; 18: 250-259.
6. Zitvogel L, Kepp O, Kroemer G. Decoding cell death signals in inflammation and immunity. Cell 2010; 140: 798-804.
7. Palm NW, Medzhitov R. Pattern recognition receptors and control of adaptive immunity. Immunol Rev 2009; 227: 221-233.
8. Krysko DV, Kaczmarek A, Krysko O, Heyndrickx L, Woznicki J, Bogaert P et al. TLR-2 and TLR-9 are sensors of apoptosis in a mouse model of doxorubicin-induced acute inflammation. Cell Death Differ 2011; 18: 1316-1325.
9. Dudek AM, Garg AD, Krysko DV, De Ruysscher D, Agostinis P. Inducers of immunogenic cancer cell death. Cytokine Growth Factor Rev 2013; e-pub ahead of print, 4 February 2013. doi: pii: S1359-6101(13)00006-3.10.1016/j.cytogfr.2013. 01.005.
10. Panaretakis T, Kepp O, Brockmeier U, Tesniere A, Bjorklund AC, Chapman DC et al. Mechanisms of pre-apoptotic calreticulin exposure in immunogenic cell death. EMBO J 2009; 28: 578-590.
11. Garg AD, Krysko DV, Verfaillie T, Kaczmarek A, Ferreira GB, Marysael T et al. A novel pathway combining calreticulin exposure and ATP secretion in immunogenic cancer cell death. EMBO J 2012; 31: 1062-1079.
12. Krysko DV, Garg AD, Kaczmarek A, Krysko O, Agostinis P, Vandenabeele P. Immunogenic cell death and DAMPs in cancer therapy. Nat Rev Cancer 2012; 12: 860-875.
13. Obeid M, Tesniere A, Ghiringhelli F, Fimia GM, Apetoh L, Perfettini JL et al. Calreticulin exposure dictates the immunogenicity of cancer cell death. Nat Med 2007; 13: 54-61.
14. Casares N, Pequignot MO, Tesniere A, Ghiringhelli F, Roux S, Chaput N et al. Caspase-dependent immunogenicity of doxorubicin-induced tumor cell death. J Exp Med 2005; 202: 1691-1701.
15. Ciampricotti M, Hau CS, Doornebal CW, Jonkers J, de Visser KE. Chemotherapy response of spontaneous mammary tumors is independent of the adaptive immune system. Nat Med 2012; 18: 344-346.
16. He Y, Zha J, Wang Y, Liu W, Yang X, Yu P. Tissue damage-associated 'danger signals' influence T cell responses that promote the progression of pre-neoplasia to cancer. Cancer Res 2012; 73: 629-639.
17. Tang D, Kang R, Livesey KM, Cheh CW, Farkas A, Loughran P et al. Endogenous HMGB1 regulates autophagy. J Cell Biol 2010; 190: 881-892.
18. Liu L, Yang M, Kang R, Wang Z, Zhao Y, Yu Y et al. HMGB1-induced autophagy promotes chemotherapy resistance in leukemia cells. Leukemia 2011; 25: 23-31.
19. Liu L, Yang M, Kang R, Wang Z, Zhao Y, Yu Y et al. DAMP-mediated autophagy contributes to drug resistance. Autophagy 2011; 7: 112-114.
20. Chiba S, Baghdadi M, Akiba H, Yoshiyama H, Kinoshita I, Dosaka-Akita H et al. Tumor-infiltrating DCs suppress nucleic acid-mediated innate immune responses through interactions between the receptor TIM-3 and the alarmin HMGB1. Nat Immunol 2012; 13: 832-842.
21. Heijmans J, Buller NV, Hoff E, Dihal AA, van der Poll T, van Zoelen MA et al. Rage signalling promotes intestinal tumourigenesis. Oncogene 2012; 32: 1202-1206.
22. 2+-binding chaperone of the endoplasmic reticulum. Int J Biochem Cell Biol 2005; 37: 260-266.
23. Gold LI, Eggleton P, Sweetwyne MT, Van Duyn LB, Greives MR, Naylor SM et al. Calreticulin: non-endoplasmic reticulum functions in physiology and disease. FASEB J 2010; 24: 665-683.
24. Garg AD, Kaczmarek A, Krysko O, Vandenabeele P, Krysko DV, Agostinis P. ER stress-induced inflammation: does it aid or impede disease progression? Trends Mol Med 2012; 18: 589-598.
25. Garg AD, Krysko DV, Vandenabeele P, Agostinis P. The emergence of phox-ER stress induced immunogenic apoptosis. OncoImmunology 2012; 1: 786-788.
26. Fucikova J, Kralikova P, Fialova A, Brtnicky T, Rob L, Bartunkova J et al. Human tumor cells killed by anthracyclines induce a tumor-specific immune response. Cancer Res 2011; 71: 4821-4833.
27. Zappasodi R, Pupa SM, Ghedini GC, Bongarzone I, Magni M, Cabras AD et al. Improved clinical outcome in indolent B-cell lymphoma patients vaccinated with autologous tumor cells experiencing immunogenic death. Cancer Res 2010; 70: 9062-9072.
28. Wemeau M, Kepp O, Tesniere A, Panaretakis T, Flament C, De Botton S et al. Calreticulin exposure on malignant blasts predicts a cellular anticancer immune response in patients with acute myeloid leukemia. Cell Death Dis 2010; 1: e104.
29. Fredly H, Ersvaer E, Gjertsen BT, Bruserud O. Immunogenic apoptosis in human acute myeloid leukemia (AML): primary human AML cells expose calreticulin and release heat shock protein (HSP) 70 and HSP90 during apoptosis. Oncol Rep 2011; 25: 1549-1556.
30. Liu R, Gong J, Chen J, Li Q, Song C, Zhang J et al. Calreticulin as a potential diagnostic biomarker for lung cancer. Cancer Immunol Immunother 2012; 61: 855-864.
31. Elliott MR, Chekeni FB, Trampont PC, Lazarowski ER, Kadl A, Walk SF et al. Nucleotides released by apoptotic cells act as a find-me signal to promote phagocytic clearance. Nature 2009; 461: 282-286.
32. Martins I, Tesniere A, Kepp O, Michaud M, Schlemmer F, Senovilla L et al. Chemotherapy induces ATP release from tumor cells. Cell Cycle 2009; 8: 3723-3728.
33. Ayna G, Krysko DV, Kaczmarek A, Petrovski G, Vandenabeele P, Fesus L. ATP release from dying autophagic cells and their phagocytosis are crucial for inflammasome activation in macrophages. PLoS One 2012; 7: e40069.
34. Chekeni FB, Elliott MR, Sandilos JK, Walk SF, Kinchen JM, Lazarowski ER et al. Pannexin 1 channels mediate 'find-me' signal release and membrane permeability during apoptosis. Nature 2010; 467: 863-867.
35. Michaud M, Martins I, Sukkurwala AQ, Adjemian S, Ma Y, Pellegatti P et al. Autophagy-dependent anticancer immune responses induced by chemotherapeutic agents in mice. Science 2011; 334: 1573-1577.
36. Martins I, Michaud M, Sukkurwala AQ, Adjemian S, Ma Y, Shen S et al. Premortem autophagy determines the immunogenicity of chemotherapy-induced cancer cell death. Autophagy 2012; 8: 3.
37. Ghiringhelli F, Apetoh L, Tesniere A, Aymeric L, Ma Y, Ortiz C et al. Activation of the NLRP3 inflammasome in dendritic cells induces IL-1beta-dependent adaptive immunity against tumors. Nat Med 2009; 15: 1170-1178.
38. Idzko M, Dichmann S, Ferrari D, Di Virgilio F, la Sala A, Girolomoni G et al. Nucleotides induce chemotaxis and actin polymerization in immature but not mature human dendritic cells via activation of pertussis toxin-sensitive P2y receptors. Blood 2002; 100: 925-932.
39. Myrtek D, Idzko M. Chemotactic activity of extracellular nucleotideson human immune cells. Purinergic Signal 2007; 3: 5-11.
40. la Sala A, Sebastiani S, Ferrari D, Di Virgilio F, Idzko M, Norgauer J et al. Dendritic cells exposed to extracellular adenosine triphosphate acquire the migratory properties of mature cells and show a reduced capacity to attract type 1 T lymphocytes. Blood 2002; 99: 1715-1722.
41. Zhang Y, Gong LH, Zhang HQ, Du Q, You JF, Tian XX et al. Extracellular ATP enhances in vitro invasion of prostate cancer cells by activating Rho GTPase and upregulating MMPs expression. Cancer Lett 2010; 293: 189-197.
42. Ryu JK, Choi HB, Hatori K, Heisel RL, Pelech SL, McLarnon JG et al. Adenosine triphosphate induces proliferation of human neural stem cells: role of calcium and p70 ribosomal protein S6 kinase. J Neurosci Res 2003; 72: 352-362.
43. Robson SC, Sevigny J, Zimmermann H. The E-NTPDase family of ectonucleotidases: structure function relationships and pathophysiological significance. Purinergic Signal 2006; 2: 409-430.
44. Beavis PA, Stagg J, Darcy PK, Smyth MJ. CD73: a potent suppressor of antitumor immune responses. Trends Immunol 2012; 33: 231-237.
45. Ohta A, Gorelik E, Prasad SJ, Ronchese F, Lukashev D, Wong MK et al. A2A adenosine receptor protects tumors from antitumor T cells. Proc Natl Acad Sci USA 2006; 103: 13132-13137.
46. Pellegatti P, Raffaghello L, Bianchi G, Piccardi F, Pistoia V, Di Virgilio F. Increased level of extracellular ATP at tumor sites: in vivo imaging with plasma membrane luciferase. PLoS One 2008; 3: e2599.
47. Trabanelli S, Ocadlikova D, Gulinelli S, Curti A, Salvestrini V, de Paula Vieira R et al. Extracellular ATP exerts opposite effects on activated and regulatory CD4 + T cells via purinergic P2 receptor activation. J Immunol 2012; 189: 1303-1310.
48. la Sala A, Ferrari D, Corinti S, Cavani A, Di Virgilio F, Girolomoni G. Extracellular ATP induces a distorted maturation of dendritic cells and inhibits their capacity to initiate Th1 responses. J Immunol 2001; 166: 1611-1617.
49. Tang D, Kang R, Zeh HJ 3rd, Lotze MT. High-mobility group box 1 and cancer. Biochim Biophys Acta 2010; 1799: 131-140.
50. Andersson U, Tracey KJ. HMGB1 is a therapeutic target for sterile inflammation and infection. Annu Rev Immunol 2011; 29: 139-162.
51. Wang H, Bloom O, Zhang M, Vishnubhakat JM, Ombrellino M, Che J et al. HMG-1 as a late mediator of endotoxin lethality in mice. Science 1999; 285: 248-251.
52. Palumbo R, Sampaolesi M, De Marchis F, Tonlorenzi R, Colombetti S, Mondino A et al. Extracellular HMGB1, a signal of tissue damage, induces mesoangioblast migration and proliferation. J Cell Biol 2004; 164: 441-449.
53. Schlueter C, Weber H, Meyer B, Rogalla P, Roser K, Hauke S et al. Angiogenetic signaling through hypoxia: HMGB1: an angiogenetic switch molecule. Am J Pathol 2005; 166: 1259-1263.
54. Mitola S, Belleri M, Urbinati C, Coltrini D, Sparatore B, Pedrazzi M et al. Cutting edge: extracellular high mobility group box-1 protein is a proangiogenic cytokine. J Immunol 2006; 176: 12-15.
55. Sorci G, Riuzzi F, Arcuri C, Giambanco I, Donato R. Amphoterin stimulates myogenesis and counteracts the antimyogenic factors basic fibroblast growth factor and S100B via RAGE binding. Mol Cell Biol 2004; 24: 4880-4894.
56. Straino S, Di Carlo A, Mangoni A, De Mori R, Guerra L, Maurelli R et al. High-mobility group box 1 protein in human and murine skin: involvement in wound healing. J Invest Dermatol 2008; 128: 1545-1553.
57. Degryse B, Bonaldi T, Scaffidi P, Muller S, Resnati M, Sanvito F et al. The high mobility group (HMG) boxes of the nuclear protein HMG1 induce chemotaxis and cytoskeleton reorganization in rat smooth muscle cells. J Cell Biol 2001; 152: 1197-1206.
58. Porto A, Palumbo R, Pieroni M, Aprigliano G, Chiesa R, Sanvito F et al. Smooth muscle cells in human atherosclerotic plaques secrete and proliferate in response to high mobility group box 1 protein. FASEB J 2006; 20: 2565-2566.
59. Chavakis E, Hain A, Vinci M, Carmona G, Bianchi ME, Vajkoczy P et al. High-mobility group box 1 activates integrin-dependent homing of endothelial progenitor cells. Circ Res 2007; 100: 204-212.
60. Yanai H, Ban T, Taniguchi T. High-mobility group box family of proteins: ligand and sensor for innate immunity. Trends Immunol 2012; 33: 633-640.
61. Scaffidi P, Misteli T, Bianchi ME. Release of chromatin protein HMGB1 by necrotic cells triggers inflammation. Nature 2002; 418: 191-195.
62. Apetoh L, Ghiringhelli F, Tesniere A, Obeid M, Ortiz C, Criollo A et al. Toll-like receptor 4-dependent contribution of the immune system to anticancer chemotherapy and radiotherapy. Nat Med 2007; 13: 1050-1059.
63. Arnold T, Michlmayr A, Baumann S, Burghuber C, Pluschnig U, Bartsch R et al. Plasma HMGB-1 after the initial dose of epirubicin/docetaxel in cancer. Eur J Clin Invest 2013; 43: 286-291.
64. Bergmann C, Bachmann HS, Bankfalvi A, Lotfi R, Putter C, Wild CA et al. Toll-like receptor 4 single-nucleotide polymorphisms Asp299Gly and Thr399Ile in head and neck squamous cell carcinomas. J Transl Med 2011; 9: 139.
65. Tesniere A, Schlemmer F, Boige V, Kepp O, Martins I, Ghiringhelli F et al. Immunogenic death of colon cancer cells treated with oxaliplatin. Oncogene 2010; 29: 482-491.
66. Curtin JF, Liu N, Candolfi M, Xiong W, Assi H, Yagiz K et al. HMGB1 mediates endogenous TLR2 activation and brain tumor regression. PLoS Med 2009; 6: e10.
67. Taguchi A, Blood DC, del Toro G, Canet A, Lee DC, Qu W et al. Blockade of RAGE-amphoterin signalling suppresses tumour growth and metastases. Nature 2000; 405: 354-360.
68. Maeda S, Hikiba Y, Shibata W, Ohmae T, Yanai A, Ogura K et al. Essential roles of high-mobility group box 1 in the development of murine colitis and colitis-associated cancer. Biochem Biophys Res Commun 2007; 360: 394-400.
69. Luo Y, Chihara Y, Fujimoto K, Sasahira T, Kuwada M, Fujiwara R et al. High mobility group box 1 released from necrotic cells enhances regrowth and metastasis of cancer cells that have survived chemotherapy. Eur J Cancer 49: 741-751.
70. Martins I, Kepp O, Schlemmer F, Adjemian S, Tailler M, Shen S et al. Restoration of the immunogenicity of cisplatin-induced cancer cell death by endoplasmic reticulum stress. Oncogene 2011; 30: 1147-1158.
71. Tang D, Kang R, Cheh CW, Livesey KM, Liang X, Schapiro NE et al. HMGB1 release and redox regulates autophagy and apoptosis in cancer cells. Oncogene 2010; 29: 5299-5310.
72. Chaiswing L, Oberley TD. Extracellular/microenvironmental redox state. Antioxid Redox Signal 2010; 13: 449-465.
73. Kazama H, Ricci JE, Herndon JM, Hoppe G, Green DR, Ferguson TA. Induction of immunological tolerance by apoptotic cells requires caspase-dependent oxidation of high-mobility group box-1 protein. Immunity 2008; 29: 21-32.
74. Kaczmarek A, Vandenabeele P, Krysko DV. Necroptosis: the release of damage-associated molecular patterns and its physiological relevance. Immunity 2013; 38: 209-223.
75. Harrison L, Blackwell K. Hypoxia and anemia: factors in decreased sensitivity to radiation therapy and chemotherapy? Oncologist 2004; 9: 31-40.
76. Yan W, Chang Y, Liang X, Cardinal JS, Huang H, Thorne SH et al. High-mobility group box 1 activates caspase-1 and promotes hepatocellular carcinoma invasiveness and metastases. Hepatology 2012; 55: 1863-1875.
77. Tsung A, Klune JR, Zhang X, Jeyabalan G, Cao Z, Peng X et al. HMGB1 release induced by liver ischemia involves Toll-like receptor 4 dependent reactive oxygen species production and calcium-mediated signaling. J Exp Med 2007; 204: 2913-2923.
78. Yang D, Postnikov YV, Li Y, Tewary P, de la Rosa G, Wei F et al. High-mobility group nucleosome-binding protein 1 acts as an alarmin and is critical for lipopolysaccharide-induced immune responses. J Exp Med 2012; 209: 157-171.